Related Experiment Video
Updated: Mar 9, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure
Ming Zhang1, Yun-Jiu Cheng2, Jaskanwal Ds Sara3
1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Background:
Recent studies show that microRNA-145 (miRNA-145) might be an attractive tumor biomarker of considerable prognostic value, but little is known about their relationship with acute myocardial infarction (AMI). This study investigated the correlation between the level of miR-145 and AMI.
Methods:
One-hundred patients were divided into three groups: no coronary artery disease (CAD) group, non-ST segment elevation myocardial infarction group, and ST segment elevation myocardial infarction group. The plasma levels of miR-145 were quantified using real-time quantitative polymerase chain reaction. Logarithmic transformation of miRNA-145 levels (Ln_miRNA-145) was used for statistical analysis due to the skewed data distribution.
Results:
Plasma levels of miR-145 were significantly lower in patients with AMI compared to patients in the non-CAD group (-6.38 ± 0.11 vs. -4.47 ± 0.17, P< 0.0001). Compared to those without heart failure, the levels of miR-145 were significantly lower in patients with heart failure (-6.91 ± 0.20 vs. -5.35 ± 0.13, P< 0.0001). We also found that the lower plasma levels of miRNA-145 significantly correlated with increased serum levels of B-type natriuretic peptide (Spearman ρ= -0.60, P< 0.0001), troponin T (Spearman ρ= -0.62, P< 0.0001), and decreased ejection fraction (Spearman ρ= 0.65, P< 0.0001). In a multivariable linear regression analysis, AMI and heart failure were independently associated with lower Ln_miRNA-145 (estimate -0.99, standard error [SE] 0.28; P= 0.001 and estimate -0.62, SE 0.21; P= 0.004).
Conclusions:
Our results suggest that decreased plasma levels of miR-145 are associated with AMI. Circulating miR-145 may be useful in prognosticating cardiac function and the risk of developing heart failure.
Insights
Lower plasma levels of microRNA-145 (miRNA-145) are linked to acute myocardial infarction (AMI). This suggests circulating miRNA-145 may help predict cardiac function and heart failure risk.
Area of Science:
- Cardiovascular Biology
- Molecular Diagnostics
- Biomarker Research
Background:
- MicroRNA-145 (miRNA-145) shows potential as a tumor biomarker.
- The relationship between miRNA-145 and acute myocardial infarction (AMI) is not well understood.
- This study aimed to investigate the correlation between plasma miRNA-145 levels and AMI.
Purpose of the Study:
- To determine the association between plasma miR-145 levels and the presence and severity of AMI.
- To explore the correlation of miR-145 levels with indicators of cardiac dysfunction, including heart failure, B-type natriuretic peptide, troponin T, and ejection fraction.
Main Methods:
- Plasma samples from 100 patients were analyzed, categorized into no coronary artery disease (CAD), non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction groups.
- Real-time quantitative polymerase chain reaction (qPCR) was used to quantify plasma miR-145 levels.
- Logarithmic transformation (Ln_miRNA-145) and statistical analyses, including Spearman correlation and multivariable linear regression, were employed.
Main Results:
- Plasma miR-145 levels were significantly lower in patients with AMI compared to controls (P<0.0001).
- Patients with heart failure exhibited significantly lower miR-145 levels compared to those without (P<0.0001).
- Lower miR-145 levels correlated with increased B-type natriuretic peptide (Spearman ρ= -0.60) and troponin T (Spearman ρ= -0.62), and decreased ejection fraction (Spearman ρ= 0.65). AMI and heart failure were independently associated with lower Ln_miRNA-145 (P=0.001 and P=0.004, respectively).
Conclusions:
- Decreased plasma miR-145 levels are significantly associated with AMI.
- Circulating miR-145 may serve as a valuable biomarker for assessing cardiac function and predicting the risk of heart failure in patients with or at risk for AMI.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs